Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meena Subramanyam

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Bioanalysis|February 22, 2013
Clinical development of biosimilars: an evolving landscapeMeena Subramanyam
Journal of Immunotoxicology|October 30, 2008
Immunogenicity of biotherapeutics-an overviewMeena Subramanyam
Drug Discovery Today. Technologies|December 17, 2016
Translational biomarkers: from discovery and development to clinical practiceMeena Subramanyam, Jaya Goyal
The New England Journal of Medicine|September 27, 2013
More on JC viremia in natalizumab-treated patients with multiple sclerosisMeena Subramanyam, Shibeshih Belachew, Teresa Compton
Annals of Neurology|March 13, 2010
Reply: To PMID 19798640James Woodworth, Meena Subramanyam, Mark Rogge
The AAPS Journal|August 31, 2013
2012 AAPS National Biotech Conference Open Forum: a perspective on the current state of immunogenicity prediction and risk managementManoj Rajadhyaksha, Meena Subramanyam, Bonnie Rup
Bioanalysis|June 26, 2015
Incurred sample reproducibility and stability assessment in a cell-based drug concentration assayJoleen T White, Mary Crossman, Meena Subramanyam
Annals of Neurology|January 20, 2011
Assay design and sample collection can affect anti-John Cunningham virus antibody detectionSusan E Goelz, Leonid Gorelik, Meena Subramanyam
Journal of Immunological Methods|December 7, 2010
Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug developmentAlvydas Mikulskis, Dave Yeung, Meena Subramanyam, et al.
Clinical Chemistry|September 20, 2008
Increased plasma concentrations of cytoskeletal and Ca2+-binding proteins and their peptides in psoriasis patientsTatiana Plavina, Marina Hincapie, Eric Wakshull, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Bioanalysis|February 22, 2013
Clinical development of biosimilars: an evolving landscapeMeena Subramanyam
Journal of Immunotoxicology|October 30, 2008
Immunogenicity of biotherapeutics-an overviewMeena Subramanyam
Drug Discovery Today. Technologies|December 17, 2016
Translational biomarkers: from discovery and development to clinical practiceMeena Subramanyam, Jaya Goyal
The New England Journal of Medicine|September 27, 2013
More on JC viremia in natalizumab-treated patients with multiple sclerosisMeena Subramanyam, Shibeshih Belachew, Teresa Compton
Annals of Neurology|March 13, 2010
Reply: To PMID 19798640James Woodworth, Meena Subramanyam, Mark Rogge
The AAPS Journal|August 31, 2013
2012 AAPS National Biotech Conference Open Forum: a perspective on the current state of immunogenicity prediction and risk managementManoj Rajadhyaksha, Meena Subramanyam, Bonnie Rup
Bioanalysis|June 26, 2015
Incurred sample reproducibility and stability assessment in a cell-based drug concentration assayJoleen T White, Mary Crossman, Meena Subramanyam
Annals of Neurology|January 20, 2011
Assay design and sample collection can affect anti-John Cunningham virus antibody detectionSusan E Goelz, Leonid Gorelik, Meena Subramanyam
Journal of Immunological Methods|December 7, 2010
Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug developmentAlvydas Mikulskis, Dave Yeung, Meena Subramanyam, et al.
Clinical Chemistry|September 20, 2008
Increased plasma concentrations of cytoskeletal and Ca2+-binding proteins and their peptides in psoriasis patientsTatiana Plavina, Marina Hincapie, Eric Wakshull, et al.
Pageof 4